4,901 trials
Infections, Papillomavirus
Primary: Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies — 5844.6; 10500.9; 7741.6; 13045.3 EL.U/mL
Healthy
Primary: AUC0-72 of Linagliptin — 278; 279 nmol*h/L
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Primary: Peak Plasma Concentration (Cmax) of 2% Diltiazem — 0.340; 0.624 ng / mL
Cervical Cancer · Nonneoplastic Condition · Precancerous Condition
Primary: Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0 — 6.0 Grade 3/4 adverse events per 100 patient
Smoking Cessation
Primary: Area Under the Curve From Time 0 to Time 't' [AUC(0-t)] of Nicotine 2 mg Test and Reference Product — 11.49; 10.24 hr*ng/mL
Healthy
Primary: Adverse Events That Meet Dose-limiting Toxicity Criteria Specified in Protocol. — 0; 0; 0; 0 participants
Arthritis, Rheumatoid
Primary: Adjusted Geometric (Geo) Mean-Fold Change at End of Period 1 From Baseline in Measured Glomerular Filtration Rate (mGFR) — 0.91; 0.99 fold change
Varicose Veins
Primary: Weight-adjusted Polidocanol Cmax (Serum) — 584.1; 1188.7; 840.7; 1189.6 ng/mL
Adult Solid Tumor
Primary: Determine Maximum Tolerated Dose of TRC105 in Combination With Bevacizumab — 10 mg/kg
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-002358 — 43476 pg*h/ml
Lymphoma
Primary: Toxicity — 8; 2 participants
Acne Vulgaris
Primary: Maximum Plasma Level (Cmax) of Dapsone — 11.7; 14.1; 13.0; 17.6 Nanograms/Milliliter (ng/mL)
Pharmacokinetics
Primary: AUC (0-inf) — 126.47; 223.63 h*pg/mL
HIV Infection
Primary: Area Under Curve (AUC) (0-24) of Abacavir on Twice Daily Dosing — 10.85 h*mg/L
Oxidative Stress
Primary: Intracellular Glutathione Level — 221.5; 118.5; 508.5; 358.0 µmol/L